What do systematic reviews say?

Leflunomide vs methotrexate

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leflunomide vs methotrexate

The review found no eligible studies for this question.

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Leflunomide vs methotrexate

Leflunomide showed no clear difference in relapse compared with methotrexate (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.5 [0.22, 1.11]
  1 study · 54 participants
  Low

Intervention not reported

The intervention showed no clear difference in total number of adverse events (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.01 [0.91, 1.12]
  5 studies · 956 participants
  Low

Leflunomide vs methotrexate

Leflunomide showed no clear difference in serious adverse events* compared with methotrexate (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 11.81 [0.69, 203.68]
  1 study · 54 participants
  Low

Leflunomide vs methotrexate

Leflunomide showed no clear difference in infection compared with methotrexate (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.17 [0.27, 106.88]
  1 study · 54 participants
  Low

Intervention not reported

The intervention may leads to higher serious infections (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 1.26 [1.03, 1.54]
  5 studies · 956 participants
  Low

Pulse cyclophosphamide vs continuous cyclophosphamide

Pulse cyclophosphamide showed no clear difference in death at final compared with continuous cyclophosphamide (low certainty).

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  RR 0.77 [0.44, 1.32]
  4 studies · 278 participants
  Low

Pulse cyclophosphamide vs continuous cyclophosphamide

• Interventions for renal vasculitis in adults 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 52 participants
  Low

Mohs micrographic surgery vs surgical excision

Mohs micrographic surgery showed no clear difference in recurrence at 3 years compared with surgical excision (low certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 0.64 [0.16, 2.64]
  1 study · 331 participants
  Low
• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 0.61 [0.18, 2.04]
  1 study · 259 participants
  Low

Imiquimod vs surgical excision

The review found no eligible studies for this question.

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radiotherapy vs surgical excision

Radiotherapy may leads to higher recurrence at 3 years compared with surgical excision (with or without frozen section margin control) (low certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 19.11 [1.12, 325.78]
  1 study · 347 participants
  Low
• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 11.06 [1.44, 84.77]
  1 study · 347 participants
  Low

Radiotherapy vs surgical excision

Radiotherapy probably leads to lower cosmetic outcome (good/excellent) compared with surgical excision (with or without frozen section margin control) (moderate certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 0.76 [0.63, 0.91]
  1 study · 347 participants
  Moderate

Radiotherapy vs surgical excision

The review found no eligible studies for this question.

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Radiotherapy vs surgical excision

The review found no eligible studies for this question.

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

MAL‐PDT vs surgical excision

MAL‐PDT may leads to higher recurrence at 3 years compared with surgical excision (low certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 26.47 [1.63, 429.92]
  1 study · 68 participants
  Low

MAL‐PDT vs surgical excision

MAL‐PDT probably leads to higher cosmetic outcome (excellent/good) compared with surgical excision (moderate certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 1.18 [1.09, 1.27]
  2 studies · 309 participants
  Moderate

MAL‐PDT vs surgical excision

MAL‐PDT showed no clear difference in pain compared with surgical excision (low certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 2.2 [0.6, 8.03]
  1 study · 101 participants
  Low

MAL‐PDT vs surgical excision

MAL‐PDT probably leads to higher early treatment failure compared with surgical excision (moderate certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 6.66 [1.22, 36.41]
  2 studies · 173 participants
  Moderate

Imiquimod vs MAL‐PDT

Imiquimod cream probably leads to lower recurrence at 3 years compared with MAL‐PDT (moderate certainty).

• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 0.44 [0.32, 0.62]
  1 study · 277 participants
  Moderate
• Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
  RR 0.42 [0.31, 0.57]
  1 study · 228 participants
  Moderate